TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 101 filers reported holding TURNING POINT THERAPEUTICS I in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $53,479,000 | +144.2% | 710,681 | -12.9% | 0.01% | +150.0% |
| Q1 2022 | $21,903,000 | -67.2% | 815,755 | -41.7% | 0.00% | -60.0% |
| Q4 2021 | $66,714,000 | -53.5% | 1,398,603 | -35.2% | 0.01% | -54.5% |
| Q3 2021 | $143,466,000 | -40.1% | 2,159,654 | -29.6% | 0.01% | -42.1% |
| Q2 2021 | $239,471,000 | -60.4% | 3,069,360 | -52.0% | 0.02% | -63.5% |
| Q1 2021 | $604,352,000 | -20.2% | 6,389,174 | +2.8% | 0.05% | -22.4% |
| Q4 2020 | $757,342,000 | +37.1% | 6,215,363 | -1.7% | 0.07% | +19.6% |
| Q3 2020 | $552,581,000 | +68.4% | 6,325,320 | +24.5% | 0.06% | +55.6% |
| Q2 2020 | $328,066,000 | +70.9% | 5,079,197 | +18.2% | 0.04% | +33.3% |
| Q1 2020 | $191,977,000 | -36.3% | 4,298,638 | -11.2% | 0.03% | -18.2% |
| Q4 2019 | $301,523,000 | +123.6% | 4,840,647 | +35.0% | 0.03% | +106.2% |
| Q3 2019 | $134,870,000 | +11.7% | 3,586,955 | +21.0% | 0.02% | +14.3% |
| Q2 2019 | $120,695,000 | – | 2,965,494 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,750,000 | $260,122,000 | 5.80% |
| Burrage Capital Management LLC | 72,164 | $6,826,000 | 5.53% |
| Consonance Capital Management LP | 450,396 | $42,603,000 | 4.54% |
| MPM BioImpact LLC | 269,186 | $25,462,000 | 3.20% |
| Orbimed Advisors | 2,361,327 | $223,358,000 | 2.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 81,541 | $7,711,000 | 2.04% |
| SECTORAL ASSET MANAGEMENT INC | 257,879 | $24,393,000 | 1.85% |
| Nicholas Investment Partners, LP | 218,847 | $20,701,000 | 1.44% |
| Logos Global Management LP | 140,000 | $13,243,000 | 1.29% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 16,741 | $1,584,000 | 0.86% |